Agenus Inc. (AGEN) Discusses Zydus Collaboration, World Manufacturing Growth, and Affected person Entry Initiatives Transcript

Stefanie Perna-Nacar
Chief Communications & Authorities Relations Officer

Good afternoon, everybody, and thanks for becoming a member of us immediately. I am Stefanie Nacar, Chief Communications Officer at Agenus, and welcome to our first stakeholder webcast of 2026. As we speak’s dialogue comes at a significant second for our firm, one formed by necessary progress throughout affected person entry, medical improvement and operational readiness as we enter a pivotal 12 months for Agenus and for the sufferers we serve.

Earlier than we start, a quick reminder that immediately’s dialogue will embrace forward-looking statements. These are topic to dangers and uncertainties that might trigger precise outcomes to vary. So please discuss with our SEC filings for added element. As we speak’s program is designed to replicate the total arc of momentum we’re seeing globally from manufacturing and execution to expanded affected person entry to the medical proof wanted to assist regulatory pathways.

You will hear views from leaders who’re immediately shaping this progress. Garo and I’ll focus on lately closed Zydus collaboration and what allows operationally for Agenus, an professional medical perspective on the enlargement of France’s reimbursed AAC program, together with its relevance for sarcomas and perception into how rising doctor and affected person curiosity is reshaping our medical affairs infrastructure to assist entry responsibly and at scale.

Following these discussions, Agenus’ management, together with Dr. Steven O’Day, our Chief Medical Officer; Jose Iglesias, our Chief Medical Affairs Officer; and Robin Taylor, our Chief Industrial Officer, will be a part of Garo for a stay Q&A session.